Alphagan P is a brand name of brimonidine ophthalmic, approved by the FDA in the following formulation(s):
ALPHAGAN P (brimonidine tartrate - solution/drops; ophthalmic)
Manufacturer: ALLERGAN
Approval date: March 16, 2001
Strength(s): 0.15% [RLD][AT]
Manufacturer: ALLERGAN
Approval date: August 19, 2005
Strength(s): 0.1% [RLD]
Has a generic version of Alphagan P been approved?
A generic version of Alphagan P has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Alphagan P and have been approved by the FDA:
brimonidine tartrate solution/drops; ophthalmic
Manufacturer: ALCON PHARMS LTD
Approval date: May 22, 2006
Strength(s): 0.15% [AT]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Alphagan P. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Aqueous ophthalmic formulations and methods for preserving same
Patent 5,424,078
Issued: June 13, 1995
Inventor(s): Dziabo; Anthony J. & Ripley; Paul S.
Assignee(s): Allergan, Inc.
Stabilized chlorine dioxide is a preservative for ophthalmic formulations. The stabilized chlorine dioxide, when employed as a preservative ophthalmic formulations is preferably present in an amount of from about 0.0002 or about 0.002 to about 0.02 weight/volume percent. The aqueous ophthalmic formulations, in addition to the stabilized chlorine dioxide and the water which functions as a vehicle for the formulations, contains an ophthalmically acceptable tonicity component effective to maintain the osmolality of the formulation at least about 200 mOsmol/kg, and a buffer to maintain the pH of the ophthalmic formulation within an acceptable physiological range. A method for preserving aqueous ophthalmic formulations utilizing stabilized chlorine dioxide is also set forth.Patent expiration dates:
- June 13, 2012✓
- June 13, 2012✓✓
- December 13, 2012✓
- June 13, 2012
Compositions containing therapeutically active components having enhanced solubility
Patent 6,562,873
Issued: May 13, 2003
Inventor(s): Orest; Olejnik & Edward D. S.; Kerslake
Assignee(s): Allergan, Inc.
Compositions which include therapeutically active components, solubility enhancing components other than cyclodextrins, and oxy-chloro components, wherein the oxy-chloro components are substantially effective as preservatives. In one embodiment, the oxy-chloro components are useful for preserving the therapeutically active components. In one embodiment, the oxy-chloro components include chlorite components. In a useful embodiment, the solubility enhancing components include carboxymethylcellulose.Patent expiration dates:
- July 10, 2021
- July 10, 2021✓
- January 10, 2022✓
- July 10, 2021
Compositions containing &agr;-2-adrenergic agonist components
Patent 6,627,210
Issued: September 30, 2003
Inventor(s): Orest; Olejnik & Edward D. S.; Kerslake
Assignee(s): Allergan, Inc.
Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.Patent expiration dates:
- July 18, 2021✓
- January 18, 2022✓
- July 18, 2021
Compositions containing alpha-2-adrenergic agonist components
Patent 6,641,834
Issued: November 4, 2003
Inventor(s): Orest; Olejnik & Edward D. S.; Kerslake
Assignee(s): Allergan Sales, Inc.
Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.Patent expiration dates:
- July 28, 2021✓
- January 28, 2022✓
- July 28, 2021
Compositions containing alpha-2-adrenergic agonist components
Patent 6,673,337
Issued: January 6, 2004
Inventor(s): Orest; Olejnik & Edward D. S.; Kerslake
Assignee(s): Allergan, Inc.
Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.Patent expiration dates:
- July 26, 2021✓
- January 26, 2022✓
- July 26, 2021
See also...
- Alphagan P Consumer Information (Wolters Kluwer)
- Alphagan P Consumer Information (Cerner Multum)
- Alphagan P Advanced Consumer Information (Micromedex)
- Alphagan P AHFS DI Monographs (ASHP)
- Brimonidine Consumer Information (Wolters Kluwer)
- Brimonidine ophthalmic Consumer Information (Cerner Multum)
- Brimonidine Ophthalmic Advanced Consumer Information (Micromedex)
- Brimonidine Tartrate AHFS DI Monographs (ASHP)
No comments:
Post a Comment